Abstract:Abstract Disclosure: T. Park: None. I. Goak: None. H. Jin: None. K. Lee: None. Y. Kim: None. Backgrounds: Thyrotoxic periodic paralysis (TPP) is a life-threatening complication characterized recurrent episodes of hypokalemia and muscle weakness in the setting of thyrotoxicosis. The present study aimed to describe clinical manifestation and outcome of patients admitted for TPP in emergency department (ED). Methods: This retrospective study analyzed 42 patients with TPP who were admitted ED from January 2000 through December 2020 in a single tertiary referral hospital. Their clinical characteristics were reviewed retrospectively. Results: 42 patients with TPP were identified. The mean age of the patients was 35.0±12.4 years; all were males. The month in which the most patients occurred paralysis symptoms was February (16.7%), followed by October (14.3%). 5 patients had a history of severe exertion, 7 patients had ingested a heavy carbohydrate meal, one patient had an infection, 5 patients had ingested alcohol, but more than half of the patients (57.1%) were without a precipitating cause. TPP was the first presentation of thyrotoxicosis in 85.7% of patients. The most common cause of thyrotoxicosis in TPP patients was Graves' disease (88.1%). At the time of admission, the mean potassium level was 2.77±0.93 mmol/L (reference, 3.5-5.5), mean ionized calcium level was 1.17±0.15 mmol/L (1.13-1.32), mean Free T4 level was 43.36±16.92 pmol/L (11.5-22.7). About half of the patients (47.6%) suffered at least one further attack of TPP. 28 patients (66.7%) diagnosed with Graves’ disease had anti-thyroid drugs alone and 5 patients (11.9%) with thyrotoxic relapses eventually underwent radioactive iodine therapy. None of the patients underwent surgery. Conclusions: TPP can be the presenting feature of previously undiagnosed thyrotoxicosis and should be considered in the differential diagnosis in patients presenting with acute onset of motor paralysis. At the time of the TPP attack, a detailed interview and inquiry with a thorough physical examination usually provide clues to the diagnosis. Presentation: Saturday, June 17, 2023

X-ray diffraction structure analysis of MCM-48 mesoporous silica.

Case report: thyrotoxic periodic paralysis, an unusual cause of hypokalemia

Unraveling the Clinical Complexity of Thyrotoxic Periodic Paralysis: A Case Report

SAT449 Clinical Characteristics Of Patients With Thyrotoxic Periodic Paralysis; An Experience From A Tertiary Care Hospital

Insulin-induced Severe Thyrotoxic Periodic Paralysis: A Case Report

Open and closed cortico-subcortical loops: A neuro-computational account of access to consciousness in the distractor-induced blindness paradigm

In situ alkylation of N-heterocycles in organic templated cuprous halides.

[Clinical Features of Hypokalemic Periodic Paralysis].

Research Progress of Thyrotoxic Periodic Paralysis

Thyrotoxic Periodic Paralysis With Severe Hypokalemia Precipitated by Acute Alcohol Intoxication in a Patient With Graves’ Disease

Thyrotoxic periodic paralysis-A retrospective study from southern India

COVID-19 Infection-Related Thyrotoxic Hypokalemic Periodic Paralysis

Genetic characterization of the chromosomal rearrangements that accompany the transgene insertion in the chakragati mouse mutant.

Acquired hyperkalaemia leading to periodic paralysis: an emergency department perspective

Familial hypokalemic periodic paralysis: a case induced by concurrent hyperthyroidism

Clinical Analysis on 46 Patients with Hypokalemic Periodic Paralysis

Ultrasonic treatment of biological sludge: Floc disintegration, cell lysis and inactivation.

Thyrotoxic periodic paralysis and the sodium/potassium pump

Challenging treatment of severe hypotension following tracheal intubation in a patient with primary hyperparathyroidism: A case report

Severe Hypokalemia ECG Changes Mimicking Those of Acute Coronary Syndrome (ACS) in Patient with Underlying Ischaemic Heart Disease: A Case Review

Simultaneous Cases of Familial Hypokalemic Periodic Paralysis Induced by Illicit Injection of Betamethasone